KR20230005848A - 항-trem2 항체의 사용 방법 - Google Patents

항-trem2 항체의 사용 방법 Download PDF

Info

Publication number
KR20230005848A
KR20230005848A KR1020227038069A KR20227038069A KR20230005848A KR 20230005848 A KR20230005848 A KR 20230005848A KR 1020227038069 A KR1020227038069 A KR 1020227038069A KR 20227038069 A KR20227038069 A KR 20227038069A KR 20230005848 A KR20230005848 A KR 20230005848A
Authority
KR
South Korea
Prior art keywords
trem2
antibody
subject
trem2 antibody
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038069A
Other languages
English (en)
Korean (ko)
Inventor
로버트 폴
미쉘 에프. 와드
후아 롱
오메르 리즈완 시디퀴
아르논 로센탈
펠릭스 리지아 예
샘 잭슨
Original Assignee
알렉터 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉터 엘엘씨 filed Critical 알렉터 엘엘씨
Publication of KR20230005848A publication Critical patent/KR20230005848A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227038069A 2020-04-03 2021-04-02 항-trem2 항체의 사용 방법 Pending KR20230005848A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005130P 2020-04-03 2020-04-03
US63/005,130 2020-04-03
US202063079810P 2020-09-17 2020-09-17
US63/079,810 2020-09-17
PCT/US2021/025626 WO2021203030A2 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies

Publications (1)

Publication Number Publication Date
KR20230005848A true KR20230005848A (ko) 2023-01-10

Family

ID=75674977

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038069A Pending KR20230005848A (ko) 2020-04-03 2021-04-02 항-trem2 항체의 사용 방법

Country Status (11)

Country Link
US (1) US20230183341A1 (https=)
EP (1) EP4126953A2 (https=)
JP (1) JP2023520516A (https=)
KR (1) KR20230005848A (https=)
CN (1) CN115667308A (https=)
AU (1) AU2021247286A1 (https=)
BR (1) BR112022019892A2 (https=)
CA (1) CA3172451A1 (https=)
IL (1) IL296992A (https=)
MX (1) MX2022012182A (https=)
WO (1) WO2021203030A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3601358T5 (da) * 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
CN115003699A (zh) * 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
EP4347658A4 (en) * 2021-05-28 2025-06-04 Vigil Neuroscience, Inc. TREM2 AGONIST BIOMARKER AND METHODS OF USE THEREOF
AU2022307687A1 (en) * 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023164516A1 (en) * 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023192282A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
CN117624360A (zh) 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2026062582A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062585A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7105825B2 (en) * 1999-04-14 2006-09-12 Juni Jack E Single photon emission computed tomography system
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3198933B1 (en) * 2014-09-26 2020-11-04 Sun Patent Trust Device-to-device wireless communication method and user equipment
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR102425326B1 (ko) * 2016-05-20 2022-07-25 세다르스-신나이 메디칼 센터 알츠하이머병 및 관련 병태의 치료 또는 예방 방법
CN109641961A (zh) 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
DK3601358T5 (da) * 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
CN115003699A (zh) * 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
JP7745557B2 (ja) * 2020-02-24 2025-09-29 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
WO2023164516A1 (en) * 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies

Also Published As

Publication number Publication date
WO2021203030A3 (en) 2021-11-18
MX2022012182A (es) 2022-12-08
EP4126953A2 (en) 2023-02-08
CA3172451A1 (en) 2021-10-07
IL296992A (en) 2022-12-01
BR112022019892A2 (pt) 2022-12-13
US20230183341A1 (en) 2023-06-15
WO2021203030A2 (en) 2021-10-07
JP2023520516A (ja) 2023-05-17
AU2021247286A1 (en) 2022-10-20
CN115667308A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7554247B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
KR20230005848A (ko) 항-trem2 항체의 사용 방법
US20250084165A1 (en) Methods of use of anti-trem2 antibodies
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
JP2018525999A (ja) 抗Ｓｉｇｌｅｃ−７抗体及びその使用方法
US20230024528A1 (en) Methods of use of anti-trem2 antibodies
JP7745557B2 (ja) 抗ｔｒｅｍ２抗体の使用方法
CN115066437A (zh) 使用抗cd33抗体的方法
HK40087465A (zh) 抗trem2抗体的使用方法
HK40079646A (en) Methods of use of anti-trem2 antibodies
EA050276B1 (ru) Способы применения антител к trem2
HK40079770A (en) Methods of use of anti-cd33 antibodies
EA051513B1 (ru) Способы применения антител к сортилину

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240402

Comment text: Request for Examination of Application